GlaxoSmithKline

Recent news

• Rating change
  Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $67.1
  \u5e02\u573a\u8d44\u8baf · 2026/5/29
• Rating change
  J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
  TipRanks · 2026/7/24
• Rating change
  J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 2026/9/14
• GlaxoSmithKline backs Rezera: Anti-inflammatory biotech firm Rezera (RZRA.US) plans to raise $200 million through an IPO, valuing the company at $254 million.
  Zhitong Finance · 2026/11/6
• Company notice
  6-K: Gsk Enters Agreement to Acquire Idrx, Inc.
  SEC · 2025/1/13
• Company notice
  6-K: Gsk Completes Acquisition of Idrx, Inc.
  SEC · 2025/2/24
• Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $55.9
  \u5e02\u573a\u8d44\u8baf · 2026/10/29
• GSK Target Cut to GBP21.00 From GBP25.00 by Jefferies
  Dow Jones · 2026/10/29
• Rating change
  GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
  TipRanks · 2026/10/1
• Rating change
  GlaxoSmithKline (GSK) Receives a Sell From J.P. Morgan
  TipRanks · 2026/10/22
• Company notice
  HENGRUI PHARMA: Inside Information Announcement and Overseas Regulatory Announcement - Entering into Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited and GlaxoSmithKline Intellectual Property (No. 4) Limited
  HKEX · 2025/7/28
• Rating change
  J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
  TipRanks · 2026/9/1
• Rating change
  GSK Target Raised to GBP22.00 From GBP20.00 by Berenberg
  Dow Jones · 2026/9/15
• GSK (GSK.L): Q3 2026 Review: Focus on HIV Timeline and Launch Progress
  CSOP · 2026/10/31
• Rating change
  TD Cowen Upgrades GlaxoSmithKline(GSK.US) to Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• Rating change
  J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
  TipRanks · 2026/10/8
• Rating change
  TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• Company notice
  6-K: Tesaro, A Gsk Subsidiary, Initiates Litigation Against Anaptysbio, Inc.
  SEC · 2025/11/21
• RBC Lowers Price Target on GSK to GBP19.25 From GBP19.75, Keeps Sector Perform Rating
  MT Newswires · 2026/10/29
• Company notice
  Beijing Wantai Biological Pharmacy Enterprise: Announcement from Beijing Wantai Biological Pharmacy Enterprise regarding the termination of the cooperation agreement with GSK by its wholly-owned subsidiary.
  SZSI · 2024/7/23
• GlaxoSmithKline, Inovio, and Agios are all awaiting review, as U.S. biotech stocks enter an FDA approval window for innovative drugs.
  Zhitong Finance · 2026/10/19
• GSK Target Started at GBP19.75 by RBC
  Dow Jones · 2026/9/9
• GlaxoSmithKline (GSK.US) strengthens its oncology pipeline! Acquires trispecific T-cell engager from Enmabio for up to $750 million, targeting multiple myeloma.
  Zhitong Finance · 2026/9/15
• Rating change
  TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/2/9
• Rating change
  J.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)
  TipRanks · 2026/2/25

Headlines are aggregated automatically and are not independently verified or edited by our team.